Table 6.

Event rates and hazard ratios for the primary end point correlated with estimated 10-year Framingham and Reynolds risk scores at baseline

Risk level	Event rate/100-person years, rosuvastatin 20 mg group	Event rate/100-person years, placebo group	Hazard ratio (95% CI)
Framingham 10-year risk score
<5% (n = 2791, 173 men, 2618 women)	0.22	0.34	0.64 (0.23–1.81)
5%–10% (n = 6091, 2525 women, 3566 men)	0.50	0.92	0.55 (0.36–0.84) 5-year NNT = 40a
11%–20% (n = 7340,1404 women, 5936 men)	0.95	1.84	0.51 (0.39–0.68) 5-year NNT = 18b
>20% (n = 1555, 242 women, 1313 men)	1.72	2.41	0.70 (0.43–1.14)
Reynolds 10-year risk score
<5% (n = 3583, 944 men, 2639 women)	0.26	0.41	0.62 (0.27–1.43)
5%–10% (n = 6436, 2651 women, 3785 men)	0.44	1.00	0.45 (0.29–0.68)
11%–20% (n = 5040, 1151 women, 3889 men)	1.07	1.65	0.65 (0.47–0.90)
>20% (n = 2651, 327 women, 2324 men)	1.55	2.84	0.55 (0.38–0.80)

^aNotes: Corresponds to estimated absolute risk difference between treated and placebo groups at 5 year of ≈2.5 events/100 person-years;

^bCorresponds to estimated absolute risk difference between treated and placebo groups at 5 year of ≈5.7 events/100 person-years.

Abbreviations: CI, confidence interval; NNT, number needed to treat.